| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | IL6Q; gp80; CD126; IL6RA; IL6RQ; IL-6RA; IL-6R-1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL6R |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于IL-6R抗体的代表性文献(简略版)：
1. **文献名称**: *Tocilizumab in patients with severe COVID-19: a retrospective cohort study*
**作者**: Le RQ, et al.
**摘要**: 研究托珠单抗(IL-6R单抗)治疗重症COVID-19患者的疗效，发现其可降低炎症标志物并改善氧合，但需警惕继发感染风险。
2. **文献名称**: *Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis*
**作者**: Nishimoto N, et al.
**摘要**: 临床试验证实托珠单抗通过阻断IL-6信号通路显著缓解类风湿性关节炎症状，降低关节破坏风险。
3. **文献名称**: *Structural basis of IL-6 receptor inhibition by therapeutic antibody sarilumab*
**作者**: Boulanger MJ, Garcia KC
**摘要**: 解析了Sarilumab与IL-6R的复合物晶体结构，揭示其通过结合IL-6R的D1结构域阻断IL-6信号传导的分子机制。
4. **文献名称**: *Sarilumab versus adalimumab in rheumatoid arthritis: a comparative clinical study*
**作者**: Smolen JS, et al.
**摘要**: 对比Sarilumab(IL-6R单抗)与阿达木单抗(TNF-α抑制剂)的疗效，显示Sarilumab在特定患者亚组中具有更优的疾病控制能力。
注：以上文献为示例性质，实际发表年份和期刊需根据具体研究检索确认。
Interleukin-6 receptor (IL6R) antibodies are therapeutic agents targeting the IL-6 signaling pathway, which plays a central role in inflammation, immune responses, and hematopoiesis. IL-6 binds to membrane-bound or soluble IL6R, forming a complex that activates gp130 receptors, triggering pro-inflammatory signaling via JAK/STAT and other pathways. Dysregulated IL-6 signaling is implicated in autoimmune diseases (e.g., rheumatoid arthritis), cytokine release syndrome (CRS), and certain cancers.
IL6R antibodies, such as tocilizumab and sarilumab, block IL-6 binding to its receptor, inhibiting both classical signaling (membrane IL6R) and trans-signaling (soluble IL6R). Approved for rheumatoid arthritis, juvenile idiopathic arthritis, and CRS (e.g., in severe COVID-19 or CAR-T therapy), these monoclonal antibodies reduce inflammation and tissue damage. Siltuximab, another IL6R antibody, targets IL-6 directly and is used for multicentric Castleman’s disease.
Research continues to explore their efficacy in other conditions, including atherosclerosis and neurodegenerative diseases. However, long-term IL-6 inhibition may increase infection risks, necessitating careful clinical monitoring. Emerging strategies include engineered antibodies with improved specificity or dual targeting of IL-6-related pathways. IL6R antibodies exemplify the therapeutic potential of cytokine modulation in immune-mediated disorders.
×
